stockrowMirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024.
- Revenue
- +39.6%
- EPS
- −1,136.8%
- Free cash flow
- −114.2%
- Total debt
- +136.4%
Quarter to September 2026, against a year earlier
Follow MIRM
Alert me
Mirum Pharmaceuticals, Inc. (MIRM) EV/Sales
As of 5 November 2026, Mirum Pharmaceuticals, Inc. (MIRM) trades at a EV/Sales of 9.7×. Over the past ten years it has ranged from 0.0× (March 2022) to 26.7× (April 2022); the current reading is higher than 77% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.5× | 26.20% |
| FY2024 | 5.9× | (11.62%) |
| FY2023 | 6.7× | (19.70%) |
| FY2022 | 8.3× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 8.9× | (28.98%) |
| Jun 2026 | 12.5× | 32.91% |
| Mar 2026 | 9.4× | 26.07% |
| Dec 2025 | 7.5× | (3.41%) |
| 18 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | n/m |
| IMVT Immunovant, Inc. compare | n/m |
| ORKA Oruka Therapeutics, Inc. compare | n/m |
| KOD Kodiak Sciences Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 5.4× |
| IONS Ionis Pharmaceuticals, Inc. compare | 7.0× |
| MIRM Mirum Pharmaceuticals, Inc. | 9.7× |
| LGND Ligand Pharmaceuticals Incorporated compare | 24.7× |
| CGON CG Oncology, Inc. compare | 755× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on MIRM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement